Atlas Trials

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Clinical trial NCT04338243 · UNKNOWN

Trial details

NCT number
NCT04338243
Sponsor
Haihe Biopharma Co., Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Negative T790M Mutation and Met Amplification
Start date
2019-11-18
Primary completion
2020-12-31
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.